192 related articles for article (PubMed ID: 10499621)
1. Telomerase assay for differentiating between malignancy-related and nonmalignant ascites.
Tangkijvanich P; Tresukosol D; Sampatanukul P; Sakdikul S; Voravud N; Mahachai V; Mutirangura A
Clin Cancer Res; 1999 Sep; 5(9):2470-5. PubMed ID: 10499621
[TBL] [Abstract][Full Text] [Related]
2. Applications of the telomerase assay in peritoneal washing fluids.
Tseng CJ; Jain S; Hou HC; Liu W; Pao CC; Lin CT; Horng SG; Soong YK; Hsueh S
Gynecol Oncol; 2001 Jun; 81(3):420-3. PubMed ID: 11371132
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometry in the diagnosis of peritoneal carcinomatosis.
Both CT; de Mattos AA; Neumann J; Reis MD
Am J Gastroenterol; 2001 May; 96(5):1605-9. PubMed ID: 11374707
[TBL] [Abstract][Full Text] [Related]
4. [The diagnostic value of telomerase activity in differentiating benign and malignant ascitic fluid].
Yang YL; Ma ZB; Xu HY
Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):745-7. PubMed ID: 16255881
[TBL] [Abstract][Full Text] [Related]
5. Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignancies.
Li CP; Huang TS; Chao Y; Chang FY; Whang-Peng J; Lee SD
World J Gastroenterol; 2004 Sep; 10(17):2468-71. PubMed ID: 15300886
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of detecting telomerase activity in ascites cells from patients with ovarian carcinoma].
Jin S; Zhang W; Wang H; Liu Y; Gao F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Dec; 21(6):455-9. PubMed ID: 12567493
[TBL] [Abstract][Full Text] [Related]
7. Utility of ascitic fluid analysis in patients with malignancy-related ascites.
Salerno F; Restelli B; Incerti P; Annoni G; Capozza L; Badalamenti S; Lampertico P; Mojana E; Moser P; Tommasini M
Scand J Gastroenterol; 1990 Mar; 25(3):251-6. PubMed ID: 1690913
[TBL] [Abstract][Full Text] [Related]
8. [Immunological parameters in the differential diagnosis of ascites secondary to peritoneal carcinomatosis, hepatic cirrhosis, and congestive heart failure].
Roldan-Molina F; de Oliveira e Silva A; dos Santos TE; Genzini T; de Miranda MP; de Oliveira RM; Santo GC; D'Albuquerque LA
Arq Gastroenterol; 1992; 29(2):56-61. PubMed ID: 1284885
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of telomerase activity and cytologic diagnosis in malignant ascites.
Park ES; Lee J; Kang SY; Lee EJ; Lee MH; Yoon N; Oh YL; Kim KM
Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):146-51. PubMed ID: 24344501
[TBL] [Abstract][Full Text] [Related]
10. Study of effusion cytology in patients with simultaneous malignancy and ascites.
Jha R; Shrestha HG; Sayami G; Pradhan SB
Kathmandu Univ Med J (KUMJ); 2006; 4(4):483-7. PubMed ID: 18603959
[TBL] [Abstract][Full Text] [Related]
11. Role of fibronectin in diagnosis of malignant ascites.
Sood A; Moudgil A; Sood N; Kharay AS; Kaushal S; Narang AP
J Assoc Physicians India; 1997 Apr; 45(4):283-5. PubMed ID: 12521085
[TBL] [Abstract][Full Text] [Related]
12. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
Lee WY
Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
[TBL] [Abstract][Full Text] [Related]
13. Value of ascitic fluid ferritin in the differential diagnosis of malignant ascites.
Kountouras J; Boura P; Tsapas G; Charisis K; Magoula I; Tsakiri I
Anticancer Res; 1993; 13(6B):2441-5. PubMed ID: 8135481
[TBL] [Abstract][Full Text] [Related]
14. [Expression of heparanase mRNA in ascitic cells is not a good marker in differential diagnosis of malignancies].
Cai YG; Fang DC; Yang SM; Luo YH; Chen L; Yang MH; Wang DX
Zhonghua Gan Zang Bing Za Zhi; 2005 May; 13(5):390-1. PubMed ID: 15918984
[No Abstract] [Full Text] [Related]
15. Telomerase activity, telomere length and human telomerase reverse transcriptase expression in hepatocellular carcinoma is independent of hepatitis virus status.
Saini N; Srinivasan R; Chawla Y; Sharma S; Chakraborti A; Rajwanshi A
Liver Int; 2009 Sep; 29(8):1162-70. PubMed ID: 19627485
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activity in benign and malignant cytologic fluids.
Mu XC; Brien TP; Ross JS; Lowry CV; McKenna BJ
Cancer; 1999 Apr; 87(2):93-9. PubMed ID: 10227600
[TBL] [Abstract][Full Text] [Related]
17. Human chorionic gonadotropin-beta in the differentiation of malignancy-related and nonmalignant ascites.
Gerbes AL; Hoermann R; Mann K; Jüngst D
Digestion; 1996; 57(2):113-7. PubMed ID: 8786000
[TBL] [Abstract][Full Text] [Related]
18. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma.
Miura N; Maeda Y; Kanbe T; Yazama H; Takeda Y; Sato R; Tsukamoto T; Sato E; Marumoto A; Harada T; Sano A; Kishimoto Y; Hirooka Y; Murawaki Y; Hasegawa J; Shiota G
Clin Cancer Res; 2005 May; 11(9):3205-9. PubMed ID: 15867214
[TBL] [Abstract][Full Text] [Related]
19. (1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods.
Bala L; Sharma A; Yellapa RK; Roy R; Choudhuri G; Khetrapal CL
NMR Biomed; 2008 Jul; 21(6):606-14. PubMed ID: 18205245
[TBL] [Abstract][Full Text] [Related]
20. The role of telomerase activity in hepatocellular carcinoma.
Shimada M; Hasegawa H; Gion T; Utsunomiya T; Shirabe K; Takenaka K; Otsuka T; Maehara Y; Sugimachi K
Am J Gastroenterol; 2000 Mar; 95(3):748-52. PubMed ID: 10710069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
